Economy

Perrigo Company plc Ordinary Sh (PRGO) Ownership Decreased by Parnassus Investments /ca

Perrigo Company plc Ordinary Sh (PRGO) Ownership Decreased by Parnassus Investments /ca

During the same period in the prior year, the business earned $1.32 earnings per share.

Washington Trust Company, which manages about $1.55 billion US Long portfolio, upped its stake in Chubb Limited by 42,539 shares to 51,907 shares, valued at $6.86M in 2016Q4, according to the filing. Amica Retiree Med Tru has invested 0.08% in Perrigo Company plc Ordinary Shares (NYSE:PRGO). Its position was worth $52,666,000 an increase of $28,053,000 as of quarter end. Teza Capital Management LLC acquired a new position in shares of Perrigo during the first quarter worth $205,000. Bank of Nova Scotia now owns 3,219 shares of the company's stock worth $214,000 after buying an additional 80 shares during the last quarter.

Tiaa Cref Investment Management LLC downsized its stake by shedding 545 shares a decrease of 0.2% in the quarter. BB&T Securities LLC now owns 9,062 shares of the company's stock worth $684,000 after buying an additional 35 shares during the last quarter. Vanguard Group Inc. now owns 14,574,768 shares of the company's stock valued at $967,619,000 after buying an additional 633,343 shares in the last quarter.

Perrigo Company plc (PRGO)'s current session activity disclosed discouraging signal for active traders.

The company has a one year high of $99.14 and a one year low of $63.68.

The stock last traded at $78.49 significantly above $73.48, the stock's 50 day moving average and which is quite a bit above the 200 day moving average of $73.02.

Director, Parker Geoffrey M., purchased 2,500 common shares of Perrigo Company plc (PRGO) in the open market. Company fiscal year is ending in December and analysts' consensus recommendation is Hold for PRGO and estimated EPS for next quarter is $ 1.10. Perrigo had a positive return on equity of 11.79% and a negative net margin of 43.81%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the firm posted $1.32 EPS. The business's revenue was down 7.7% compared to the same quarter a year ago.

More news: Pentagon Ready to 'Fight Tonight' as Tensions Between US, North Korea Escalate
More news: Equities fall on rising tension between US & North Korea
More news: More possibly tainted eggs found in Britain

Perrigo Company plc on 3/30/2017 reported its EPS as $1.93 with the analysts projecting the EPS of the stock as $1.98. Additionally the company recently declared a dividend that was paid on Tuesday June 13th, 2017. Investors of record on Friday, August 25th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.96%.

On 5/3/2017 announced a quarterly dividend of $0.16 0.88% with an ex dividend date of 5/24/2017 which will be payable on 5/26/2017. Perrigo's dividend payout ratio is -3.90%. If you are accessing this piece of content on another publication, it was stolen and republished in violation of USA and global copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/12/perrigo-company-prgo-given-hold-rating-at-stifel-nicolaus.html.

Several equities research analysts recently issued reports on the company.

On November 11 the company was upgraded from "Market Perform" to "Neutral" by analysts at Bank of America. Finally, Royal Bank Of Canada restated a "hold" rating and issued a $66.00 price objective on shares of Perrigo in a report on Wednesday, May 24th.

In a report released today, Randall Stanicky from RBC Capital assigned a Sell rating to Perrigo Company (NYSE: PRGO), with a price target of $64. Needham maintained the shares of IIVI in report on Wednesday, June 21 with "Buy" rating.

Starboard Value Lp holds 23.32% of its portfolio in Perrigo Company plc Ordinary Shares for 9.51 million shares.

It offers OTC products in various categories, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic products, natural health and vitamins, personal care and derma-therapeutics, lifestyle, and anti-parasite; consumer healthcare products; and vitamins, minerals, and supplements.